Printer friendly version Share


Coming soon: World’s Largest Gastrointestinal Cancer Congress

28 June 2017 — 01 July 2017 European Society for Medical Oncology (ESMO)

Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 19th ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 28 June to 1 July 2017.

The World GI Congress is the premier global event in the field – encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and rare tumours.

Colorectal and stomach cancers are among the most common cancers in the world.1 Many unmet needs exist in certain cancers such as pancreatic, liver and gall bladder cancers, which are among the most common causes of death worldwide.2

There are currently hundreds of ongoing studies in the field of GI malignancies and the ESMO 19th World Congress on Gastrointestinal Cancer will present the latest research with a potential to change outcomes for patients worldwide.

Scientific Programme:

Over 425 abstracts were accepted for presentation at the ESMO 19th World Congress on Gastrointestinal Cancer, including research on:

·         Liquid biopsies

·         The role of the microbiome in cancer medicine

·         Immune mechanisms and immune therapy in GI cancer

·         New drugs

Molecular markers

Further information on the congress agenda can be found here:

Abstracts presented at World GI Congress will be published on 28 June in a supplement of Annals of Oncology.

Embargo information

Oral and late breaking abstracts selected by the Scientific Committee for presentation at World GI Congress are embargoed until the end of the scientific session during which they are presented. Oral abstracts scheduled for presentation include:

Wednesday, 28 June 2017

·         PEGPH20 Improves PFS in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Phase 2 Study in Combination With nab-Paclitaxel/Gemcitabine +

Andrew Hendifar, et al., O-003

·         Tumor Hyaluronan May Predict Benefit from PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)

Andrew Hendifar, et al., O-028 

Thursday, 29 June 2017

·         Nivolumab Monotherapy in Patients with Advanced Gastric of Gastroesophageal Junction (GEJ) Cancer and 2 or More Prior Treatment Regimens: Sub-Analysis of the CheckMate 032 Study

Patrick Ott, et al., O-007

·         Efficacy and Safety of Nivolumab in Patients with Advanced Hepatocellular Carcinoma Analyzed by Patient Age: A Sub-Analysis of the CheckMate 040 Study

Ignacio Melero, et al., O-008

·         Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment

Jordi Bruix, et al., O-009

Friday, 30 June 2017

·         Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients

Aparna Parikh, et al., O-001

·         Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC)

Enrique Sanz-García, et al., O-010

·         RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)

Filippo Pietrantonio, et al., O-011

·         Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial

Eric Van Cutsem, et al., O-012

·         The prognostic impact of primary tumor location in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis

Yuichi Goto, et al., O-013

·         Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status

Julien Taieb, et al., O-015

·         Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs)

Stephanie Reyes, et al., O-021

·         Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia

Mark Eccleston, et al., O-022

·         Mediterranean diet components are negatively associated with advanced colorectal polyps in a population-based case-control study

Naomi Fliss Isakov, et al., O-023

·         Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?

Garry Mahon, et al., O-024

Saturday, 1 July 2017

·         Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall survival

Dominik Modest et al., O-029

·         Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study

Dominik Modest, et al., O-026

·         Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer

Guy van Hazel, et al., O-027 xxx

The World GI Congress will take place in the The International Convention Center of Barcelona (CCIB) and is organized by Imedex.

TON logo New Norwegian logo FNSF ad Cambridge grey garduated eNEWS-Jan 2017 Elhuyar with Basque